NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- (GLOBENEWSWIRE)—The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ:CKPT) securities during the period of March 10, 2021 through December 15, 2023, inclusive ("the Class Period"). Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
[Click here to learn more about the class action]
In January 2023, Checkpoint submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for approval of its lead antibody product candidate, cosibelimab, as a treatment for patients with ...
CKPT) Investors>Full story available on Benzinga.com